Understand the source comparison
Is Hexarelin Worth It: Peptide Comparison
Before committing to hexarelin, researchers need clarity on how it stacks against alternatives across the metrics that matter: potency, desensitization timeline, cost per effective dose, and application suitability. Hexarelin 6–8× increase at 100mcg (highest i
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before committing to hexarelin, researchers need clarity on how it stacks against alternatives across the metrics that matter: potency, desensitization timeline, cost per effective dose, and application suitability.
- Hexarelin
- 6–8× increase at 100mcg (highest in class)
- Significant decline after 4–6 weeks continuous use; 60–70% efficacy loss by week 8
- Low. Requires cycling, limiting cost-per-day advantage
- Acute GH studies, cardioprotective research, maximal-pulse protocols
- Worth it for short-duration or cycled research where potency justifies desensitization management burden
- Ipamorelin
- 2–3× increase at 100mcg
- Minimal. Maintains efficacy across 16+ weeks continuous use
- High. Stable response allows predictable long-term budgeting
- Chronic studies, body composition research, protocols requiring daily dosing
- Superior choice for extended timelines; lower potency offset by consistency
- GHRP-6
- 3–4× increase at 100mcg
- Moderate. Gradual decline but less severe than hexarelin
- Moderate. Balances potency and duration
- General GH research, appetite pathway studies (ghrelin mimetic)
- Middle-ground option; appetite stimulation may confound some metabolic studies
- GHRP-2
- 4–5× increase at 100mcg
- Moderate. Receptor downregulation evident after 8–10 weeks
- Moderate. Requires occasional breaks but less rigid than hexarelin
- Broader GH research, studies requiring potency without appetite effects
- Viable alternative when hexarelin's cardiac mechanisms aren't needed
- CJC-1295 (no DAC) + Ipamorelin
- 5–7× increase (synergistic combination)
- Low. GHRH + ghrelin receptor dual-pathway minimizes single-receptor fatigue
- High. Combination maintains response without mandatory off-cycles
- Comprehensive GH axis research, long-duration body composition studies
- Best overall for sustained research; eliminates hexarelin's desensitization problem while approaching its potency